Published in final edited form as:

J Nat Prod. 2010 March 26; 73(3): 472–475. doi:10.1021/np9005647.

Modified Phenazines from an Indonesian *Streptomyces* sp.[†]

Serge Fotso[‡], Dwi Andreas Santosa^{§,⊥}, Rasti Saraswati[§], Jongtae Yang[‡], Taifo Mahmud[‡], T. Mark Zabriskie[‡], and Philip J. Proteau^{‡,*}

[‡] Department of Pharmaceutical Sciences, College of Pharmacy, 203 Pharmacy Building, Oregon State University, Corvallis, Oregon 97331-3507

[§] Indonesian Center for Biodiversity and Biotechnology, ICBB-Complex, Jl. Cilubang Nagrak No. 62, Situgede, Bogor 16115 Indonesia

[⊥] Department of Soil and Land Resources, Faculty of Agriculture, Bogor Agricultural University, Jl. Meranti, Kampus IPB Darmaga, Bogor 16680, Indonesia

Abstract

Fractionation of the extract from the Indonesian *Streptomyces* sp. ICBB8198 as directed by the antibacterial activity delivered the known phenazine antibiotics griseoluteic acid (**1a**) and griseolutein A (**1b**), as well as two new phenazine derivatives (**2** and **3**). In addition, the known compounds spirodionic acid, dihydrosarkomycins, and 6-ethyl-4-hydroxy-3,5-dimethyl-2H-pyran-2-one (**4a**), along with the new pyrone, 3,6-diethyl-4-hydroxy-5-methyl-2H-pyran-2-one (**4b**), were isolated. We report here the isolation, structure elucidation, and antibiotic activity of the new metabolites as well as a hypothetical pathway for the formation of the new phenazine derivatives.

Phenazine antibiotics have been known since 1950, with the original discovery of griseolutein from *Streptomyces griseoluteus*.¹ Numerous members of this structural family have been described, with many being ester derivatives of griseoluteic acid, the base hydrolysis product of griseolutein A. Phenazine antibiotics are now known from a variety of microorganisms, including *Streptomyces* spp., *Pelagibacter variabilis*,² *Pantoea agglomerans*,³ *Pseudomonas* spp.,⁴ and a *Vibrio* sp.⁵ The diverse biological actions of these compounds include cytotoxicity, antibacterial, antiparasitic, and antimalarial activities.⁶ Herein we report the discovery of phenazines that have a new type of modification to the main core structure.

In the continuation of our drug discovery program focused on microorganisms isolated from the Black Water Ecosystem in Kalimantan, Indonesia,^{7, 8} the extract of *Streptomyces* sp. ICBB8198 indicated activity against *Staphylococcus aureus*, *Bacillus subtilis* and *Escherichia coli*. The extract was separated using various chromatographic methods including silica gel, Sephadex LH-20 and HPLC. The main antibacterial action was correlated to the presence of griseoluteic acid (**1a**),^{2, 9} which was identified along with the related griseolutein A¹⁰ (**1b**) by an Antibase¹¹ search and comparison with reported spectroscopic data.² In addition to these known phenazines, two new phenazine derivatives (**2** and **3**) were also isolated and characterized.

[†]Dedicated to the late Dr. John W. Daly of NIDDK, NIH, Bethesda, Maryland, and to the late Dr. Richard E. Moore of the University of Hawaii-Manoa, for their pioneering work on bioactive natural products.

* To whom correspondence should be addressed. Tel: (541) 737-5776. Fax: (541) 737-3999. phil.proteau@oregonstate.edu.

Supporting Information Available. ¹H and ¹³C NMR, HSQC, and HMBC spectra for **2**, **3**, and **4b** and a protocol for obtaining the 16S rRNA gene sequence are available. This information is available free of charge via the Internet at <http://pubs.acs.org>.

Compound **2** was obtained as a yellow solid. The molecular weight was deduced from the pseudomolecular ions at m/z 467 $[M + H]^+$ and 465 $[M - H]^-$ and the HRMS experiments supported $C_{25}H_{26}N_2O_7$ as the molecular formula. The aromatic region of the 1H NMR spectrum of **2** is similar to those of **1a** and **1b** and exhibited evidence of two spin systems consisted of three consecutive protons at δ 8.95 (dd, $J = 7.2, 1.5$ Hz), 8.49 (dd, $J = 8.8, 1.5$ Hz), 8.04 (dd, $J = 8.8, 7.2$ Hz), and two protons present as *ortho*-coupled doublets suggesting that **2** possessed the same phenazine chromophore as in **1a/1b**. The aliphatic region was more complex than those of **1a/1b**. It exhibited two methoxy signals at δ 4.17 and 3.60 instead of one. Further signals observed in the aliphatic region were an ethyl group [δ 1.06 (t) and 2.58 (q)], two methyl signals at δ 1.41 (d) and 1.31 (s), a methine, and a methylene multiplet at δ 4.02, but all of these signals appeared doubled. Confirming the observations in the 1H NMR spectrum, the ^{13}C NMR spectrum indicated signals as pairs in the 8–60 ppm range, except for the quaternary carbon at δ 62.0, the methoxy carbon at δ 56.7, and the methyl carbon at δ 7.9. Four carbonyl carbons were revealed in the HMBC spectrum, including two ketone carbonyls (δ 207.0 and 205.0), and carbons at δ 172.6 and 166.3, suggestive of ester and carboxylic acid carbons, respectively. The doubling of the carbonyl carbons could not be established from the ^{13}C NMR spectrum because these carbon resonances were not clearly observed.

The HMBC spectrum indicated correlations between H-2 (δ 8.95) and C-3 (δ 134.9), C-10a (δ 138.6) and the carbonyl at δ 166.3, which suggested a carboxylic acid moiety at C-1. Furthermore, correlations were observed between H-3 and carbons C-1 (δ 125.5), C-2 (δ 136.9) and C-4a (δ 142.6), while the methoxy protons (δ 4.17), H-7 (δ 7.70) and H-8 (δ 7.12) were correlated to C-9 (δ 153.4). Observation of weak correlations from the methylene protons at δ 4.02 to carbons at δ 127.7 (C-6), 144.2 (C-5a) and 133.5 (C-7) suggested a benzylic methylene (C-1') at C-6. The interpretation of these data confirmed the same phenazine core structure as seen in **1a** and **1b**.

The second part of structure **2** was determined by the interpretation of HMBC correlations of the aliphatic region: the ethyl group and the methyl doublet at δ 1.41 had correlations to the carbonyl at δ 207.0; the methyl singlet at δ 1.31 and the doublet at δ 1.41 showed cross-peaks to the carbonyl at δ 205.0; and the methoxy signal at δ 3.60 and the methyl singlet indicated correlations to the carbonyl at δ 172.6 and to the quaternary carbon at δ 61.9. All of this evidence identified a methyl 2,4-dimethyl-3,5-dioxoheptanoate fragment. This fragment was connected to the phenazine ring system through the C-1' benzylic methylene, which had HMBC correlations to the carbonyl carbons at δ 205.0 and δ 172.6 and to the quaternary carbon at δ 61.9, establishing the planar structure of **2**. The duplication of the signals in the NMR spectra may be explained by the presence of an inseparable mixture of diastereomers, in which the methyl-bearing C-4' readily epimerizes due to the acidity of H-4'. The configuration at C-2' remains unassigned.

Compound **3** was isolated as a yellow solid. The (+) ESIMS delivered the pseudomolecular ions m/z 437 $[M + H]^+$, 459 $[M + Na]^+$ and the (-)-ESIMS gave m/z 435 $[M - H]^-$, providing a molecular weight of m/z 436. The HRMS experiment suggested the molecular formula of $C_{24}H_{24}N_2O_6$, indicating a difference of CH_2O between the molecular formulas for **2** and **3**. The 1H and ^{13}C NMR data revealed the presence of only a single methoxy group in **3**. In addition to the loss of a methoxy group, differences in the UV spectra and shift variations observed in the aromatic region of the 1H and ^{13}C NMR spectra indicated additional changes compared to **2**. For example, the 1H NMR spectrum measured in DMSO- d_6 indicated two multiplets at δ 7.75 and 6.63 integrating for four and six protons, respectively, and a broad peak at δ 11.39 (exchangeable; absent in methanol- d_4). These shift differences and the exchangeable proton suggested a dihydrophenazine core rather than the phenazine. Griseolutein B, which is a dihydrophenazine derivative, has also been observed to have an exchangeable proton in its 1H NMR spectrum, shifted downfield due to a hydrogen bond with

the acid carbonyl at C-1.¹² For a better understanding of the aromatic spin system, additional ¹H NMR spectra were measured in CDCl₃ and in methanol-*d*₄, which provided greater resolution in the aromatic region. The ¹H, ¹H-COSY spectrum indicated two aromatic spin systems (1,2,3-trisubstituted and 1,2,3,4-tetrasubstituted aromatic rings) as in **2**. Interpretation of the HMBC spectrum indicated correlations of H-7, H-8, the methoxy protons, and the protons at δ 11.39 to the carbon at δ 144.5 (C-9) confirming the position of the aromatic methoxy group, and supporting an NH at N-10, consistent with a dihydrophenazine moiety (Figure 2). With the location of the aromatic methoxy secured, it is established that the methyl ester in **2** is no longer present in the structure of **3**. In the aliphatic region, three pairs of methyl protons, which appear as a singlet, a doublet and a triplet, and a pair of methine protons at δ 2.27 and 2.36, were observed, similar to those seen in the ¹H NMR spectrum of **2**. The methylene protons at δ 3.22/δ 2.75, the methine at δ 4.24, and the methoxy at δ 3.77 were not split into paired signals. The ¹³C NMR spectrum indicated all carbons as pairs of very close signals. Resonances for four carbonyl carbons, including two ketones, were clearly visible. A final connection in the structure was made between N-5 of the dihydrophenazine and the C-2' carbonyl carbon (δ 168.2), resulting in the core structure of **3**. This linkage explains the absence of the methyl ester moiety in **3**, and is consistent with no observable N-5 proton. Although there are few protons available in this lactam ring to verify this new structural element through standard NMR experiments, the shifts of the C-1' methylene protons in **3** (δ 3.22/δ 2.75), compared to those in **2** (δ 4.02; overlapped), are consistent with the major change in magnetic environment that would occur upon cyclization into a rigid ring system. Because the protons signals are superimposable in the aromatic region and appear as pairs in the aliphatic region, **3** is also likely a mixture of epimers with the C-4' configuration the source of variability. A D₂O exchange NMR experiment supports this conclusion. The H-4' signal of **3** disappeared after treatment with D₂O, but reappeared after re-equilibration with MeOH. All attempts to separate the diastereomers of **3** have failed. The configuration at C-2' remains unassigned. Compounds **2** and **3** represent the first griseolutein derivatives that have a C-C linkage rather than a C-O linkage at C-1'. The tetracyclic nature of **3** has not previously been observed for griseolutein-derived compounds.

In addition to metabolites arising from the active fractions, two pyrones were isolated from inactive fractions. The known 6-ethyl-4-hydroxy-3,5-dimethyl-2*H*-pyran-2-one (**4a**) has been isolated previously from a *Streptomyces* sp.¹³ and from the fungus *Emericella heterothallica*.¹⁴ The minor compound **4b** was obtained as a colorless oil. HREIMS data in conjunction with NMR data supported the molecular formula of C₁₀H₁₄O₃. It was closely related to **4a** based on a comparison of the NMR data. The only difference was the presence of an additional methylene group in **4b**, representative of a second ethyl group in the structure. The extra methylene group can be introduced into **4b** at either C-3 or C-5.

Data from HMBC and NOESY experiments determined the position of this second ethyl group (Figure 3). The protons H₂-10 and H₃-11 showed HMBC correlations to C-3 (δ 105.1) and cross-peaks were seen from H₂-10 and H₃-9 to C-4 (δ 169.1). Further correlations were observed between H₂-7, H₃-8, H₃-9, and δ 161.3 (C-6/C-2 overlap), and from H₂-7 and H₃-9 to C-5 (δ 109.4) suggesting the structure of **4b** has an ethyl group at C-3. Further structure confirmation was obtained from the NOESY spectrum where distinct correlations were seen between H₃-9 and H₂-7, H₃-8 respectively. The structure was assigned as 3,6-diethyl-4-hydroxy-5-methyl-2*H*-pyran-2-one (**4b**).

The presence of the pyrones along with metabolites **2** and **3** suggested a potential route for the formation of the new phenazines. Condensation of **1b** and **4a** could lead to intermediate **A**, which could be attacked by MeOH to provide **2** directly (Figure 4), or by H₂O to form the carboxylic acid which would require conversion to the methyl ester **2**. Compound **3** could arise by intramolecular attack of N-5 of **A** onto the pyrone carbonyl, followed by reduction of the

central ring of the tricyclic system. Alternatively, **3** may be formed from **2** by similar N-5 attack on the methyl ester. Methanolysis of **3** to form **2** is another possibility, but this seems unlikely as **3** is stable in the methanol-*d*₄ NMR solvent. The potential formation of **2** via methanolysis of intermediate **A** suggests that **2** may be an isolation artifact. In order to test this hypothesis, an effort was made to detect intermediate **A** in a fresh culture by extracting with acetone, rather than an alcoholic solvent mixture. Under these conditions, **3** was observed, but no **2**, nor putative intermediate **A** was detected. This experiment supports the formation of **2** during the original isolation procedure and also argues against the formation of **3** from **2**. While **2** apparently is not a natural product, its ease of isolation when the common extraction solvent MeOH was used suggests that **2** is an isolable surrogate either for precursor **A** or for the free carboxylate equivalent of **2**. The specific rotations determined for **2** (+150) and **3** (-17) support an enzymatic condensation between griseolutein A and pyrone **4a**, forming the C-2' asymmetric center.

In addition to the phenazines and pyrones, a diastereomeric mixture of dihydrosarkomycins was also identified.^{13, 15} The collection of diverse metabolites in the ICBB8198 strain paralleled that of the spirodionic acid producer, *Streptomyces* sp. Tü6077, which produced griseoluteic acid, griseolutein, dihydrosarkomycin, and pyrone **4a**, in addition to spirodionic acid.¹³ This similarity in metabolite production with the ICBB8198 strain led us to re-examine the extract for the presence of spirodionic acid. Indeed, after growing another culture of ICBB8198 and characterizing the extract, spirodionic acid was found (characterized by MS, NMR, and comparison with literature data¹³). While there is a significant overlap in metabolites, the two *Streptomyces* strains were isolated from soil samples from distinct geographical locations (Tü6077 from the east coast of Ghana and ICBB8198 from Kalimantan, Indonesia).

Biological Activities

Compounds **2** and **3** were tested against *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, *Pseudomonas aeruginosa*, the fungus *Mucor miehei*, and the yeast *Candida albicans* in the agar diffusion test, at concentrations of 24 and 56 µg/disk, while **1a** was tested at 14 µg/disk. Compound **2** indicated activity against *Staph. aureus* with an inhibition zone of 14 mm (at 24 µg/disk) and **1a** inhibits *Staph. aureus* and *E. coli* with inhibition zones of 25 and 20 mm, respectively. Griseoluteic acid (**1a**) was mainly responsible for the high activity of the extract. Compound **3** had no antimicrobial activity.

Experimental Section

General Experimental Procedures

Optical rotations were measured on a Jasco P1010 polarimeter. UV spectra were recorded on a Beckmann DU 640 B spectrophotometer. IR spectra were recorded on a Nicolet IR100 FT-IR spectrometer. NMR spectra were measured on a Bruker Unity 300 MHz spectrometer. ESI-MS data were recorded on a ThermoFinnigan LCQ Advantage system with a quaternary Rheos 4000 pump (Flux Instrument). HRESI mass spectra were recorded on a Waters/Micromass LCT spectrometer. HREIMS and HRCIMS were measured on a JEOL HMS-600H MS route magnetic sector instrument. Preparative HPLC was performed using an RP18 column (Phenomenex, RP 100-C18, 5 µm) with the detector set at 254 nm. Flash chromatography was carried out on silica gel (230-400 mesh). Thin layer chromatography was performed on aluminum sheets with silica gel 60 F₂₅₄ (EMD chemicals Inc.). Size exclusion chromatography was done on Sephadex LH-20 (Pharmacia).

Organism Collection and Identification

The actinomycete isolation procedure was the same as previously reported.⁷ The *Streptomyces* sp. ICBB8198 culture is deposited at ICBB-CC (Indonesian Center for Biodiversity and Biotechnology Culture Collection of Microorganisms) as 0.5 mL of a 20% glycerol stock stored at -20 °C.

The 16S rRNA gene sequence (Genbank GQ470680) of *Streptomyces* sp. ICBB8198 was found to have 99.5% identity over the sequenced region to *Streptomyces* sp. LJMUEG T4 (Genbank DQ989563), isolated from a Thailand soil sample.

Fermentation and Isolation

The *Streptomyces* sp. ICBB8198 was cultivated on 6-L scale using 1-L Erlenmeyer flasks containing 250 mL of GOT medium (glycerol: 60 g/L, oatmeal: 15 g/L, tomato paste: 5 g/L, CaCO₃: 3 g/L; adjust to pH 7.0 with 1N NaOH prior to sterilization) at 29 °C for 4 days on a rotary shaker (250 rpm). The brown culture broth was mixed with Celite and filtered under vacuum. The filtered medium was passed through an HP-20 Diaion column and the resin was washed with distilled H₂O and compounds were eluted with 50% MeOH/50% acetone (EMA), followed by 100% MeOH. The residual H₂O from the methanolic extract was extracted with EtOAc (EAW). The mycelia were extracted sequentially with EtOAc (EAM) and then MeOH (MM). The extracts were evaporated to dryness separately. Four extracts were obtained, two from the mycelium (EAM, MM) and two from the broth (EAW, EMA). Bioassay of the four fractions was carried out against *Staph. aureus*, *B. subtilis*, *E. coli*, *P. aeruginosa*, *My. smegmatis*, the fungus *Mu. miehei*, and the yeast *C. albicans*. While the extracts from the broth indicated high activity against *Staph. aureus* and *B. subtilis*, the mycelium extracts were active against *E. coli* and *B. subtilis*. Column chromatography of the extract EMA on Sephadex LH-20 (3% MeOH/CH₂Cl₂) gave fractions I-IV, with high activity in fraction III. Trituration of fraction III in MeOH delivered a red powdery mixture of two compounds which were further purified by PTLC (3% MeOH/CH₂Cl₂) and identified as griseolutein A (**1b**, 5 mg) and griseoluteic acid (**1a**, 20 mg) which was responsible for the high activity against *Staph. aureus*. The purification on Sephadex LH-20 (3% MeOH/CH₂Cl₂) of the EAM extract from the mycelium gave seven fractions and only fractions 6 and 7 indicated activity against all test organisms except the fungus *M. miehei* and high activity was observed against *E. coli*. Fractions 6 and 7 were combined based on TLC similarity and the resulting material was separated on silica gel using a MeOH/CH₂Cl₂ gradient and afforded a diastereoisomeric mixture of dihydrosarkomycin (1-, 2D-NMR and MS data) which was responsible for the activity against *E. coli* and *P. aeruginosa* while the activity against the other organisms was attributed to traces of **1a**. All the other fractions were combined and repeated column chromatography on silica gel with a CH₂Cl₂/MeOH gradient gave 5-ethyl-4-hydroxy-3,5-dimethyl-2H-pyran-2-one (**4a**, 6 mg). Preparative HPLC (20% MeOH/H₂O to 100% MeOH) yielded 3,6-diethyl-4-hydroxy-5-methyl-2H-pyran-2-one (**4b**, 1.5 mg, 2nd culture 2.3 mg). The EAW extract was chromatographed on Sephadex LH-20 (50% MeOH/ CH₂Cl₂) to provide fractions A-D. Only fraction D indicated activity against *Staph. aureus*, *B. subtilis*, *E. coli*, *P. aeruginosa* and *C. albicans*. Repeated separation on Sephadex LH-20 (100% MeOH) afforded **2** (5.1 mg) and **3** (7.5 mg) in addition to griseoluteic acid (**1a**).

Compound (2)

yellow solid; [α]_D = +150 (c 0.07, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 364 (3.25), 268 (3.44), 247 (sh), 208 (3.50) nm; IR (neat) $\nu_{\max}$: 2923, 1719, 1700, 1540, 1457, 1173, 1106, 764 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75.5 MHz, CDCl₃) data: See Table 1; (+)-ESI MS m/z (%) = 467 ([M+H]⁺, 100), 489 ([M+Na]⁺, 30), 955 ([2M+Na]⁺, 85); (-)-ESI MS m/z (%): 465 ([M-H]⁺, 100), 953 ([2M-H+Na]⁺, 25); (+)-HRESIMS m/z 467.1850 [M+H]⁺

(calcd for $C_{25}H_{27}N_2O_7$, 467.1818) and 489.1619 $[M+Na]^+$ (calcd for $C_{25}H_{27}N_2O_7Na$, 467.1638).

Compound (3)

yellow powder; $[\alpha]_D = -17$ (c 0.03, MeOH); UV (MeOH) λ_{max} (log ϵ): 370 (2.75), 206 (3.13), 248 (sh), 274 (sh) nm; IR (neat) ν_{max} : 2920, 2850, 1727, 1697, 1667, 1635, 1584, 1518, 1463, 1377, 1282, 1248 cm^{-1} ; 1H NMR (300 MHz, DMSO- d_6) and ^{13}C NMR (75.5 MHz, DMSO- d_6) data: See Table 1.; 1H NMR (300 MHz, MeOH- d_4) (+)-ESIMS m/z (%) = 437 ($[M+H]^+$, 7), 459 ($[M+Na]^+$, 11), 895 ($[2M+Na]^+$, 100); (-)-ESI MS m/z (%) = 435 ($[M-H]^-$, 100), 893 ($[2M-H+Na]^+$, 15); (+)-HREIMS m/z 436.16326 (calcd for $C_{24}H_{24}N_2O_6$, 436.16344).

3,6-Diethyl-4-hydroxy-5-methyl-2H-pyran-2-one (4b)

colorless oil; UV (MeOH) λ_{max} (log ϵ): 279 (2.48), 207 (2.79) nm; IR (neat) ν_{max} 2971, 2936, 1670, 1565, 1453, 1407, 1220, 1169, 1126, 1077, 1038 cm^{-1} ; 1H NMR (300 MHz, MeOH- d_4): δ 2.58 (q, $J = 7.6$ Hz, 2H), 2.45 (q, $J = 7.4$ Hz, 2H), 1.97 (s, 3H, 3- CH_3), 1.21 (t, $J = 7.6$ Hz, 3H), 1.04 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (75.5 MHz, MeOH- d_4): 169.2 (C, C-4), 161.3 (C, C-2/C-6), 109.4 (C, C-5), 105.1 (C, C-3), 25.3 (CH_2 , C-7), 17.8 (CH_2 , C-10), 13.2 (CH_3 , C-11), 12.1 (CH_3 , C-8), 10.0 (CH_3 , C-9); (-)-ESI MS: m/z (%) = 181 ($[M-H]^-$, 100); HREIMS m/z 182.09404 (calcd for $C_{10}H_{14}O_3$, 182.09430).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

High resolution mass spectra were obtained by J. Morré at the mass spectrometry facility of the Environmental Health Sciences Center at Oregon State University, which is supported in part by a grant from NIEHS (ES00210). N. Kasanah is thanked for providing the 16S rRNA gene sequence. This work was supported by the OSU College of Pharmacy Research and Scholarship Fund. Drs. S. Grond and H-P. Fiedler are thanked for providing additional information regarding the collection site for *Streptomyces* Tü6077.

References and Notes

1. Umezawa H, Hayano S, Maeda K, Ogata Y, Okami Y. Jap Med J 1950;3:111–117.
2. Imamura N, Nishijima M, Takadera T, Adachi K, Sakai M, Sano H. J Antibiot 1997;50:8–12. [PubMed: 9066759]
3. Giddens SR, Bean DC. Int J Antimicrob Agents 2007;29:93–97. [PubMed: 17189100]
4. Budzikiewicz H. FEMS Microbiol Rev 1993;10:209–228. [PubMed: 8318257]
5. Kodama, K.; Ishii, A.; Kagasaki, T.; Shiozawa, H.; Takahashi, H. Japanese Patent JP 08217760. 1996.
6. Laursen JB, Nielsen J. Chem Rev 2004;104:1663–1686. [PubMed: 15008629]
7. Fotso S, Mahmud T, Zabriskie TM, Santosa DA, Sulastri, Proteau PJ. J Nat Prod 2008;71:61–65. [PubMed: 18081255]
8. Fotso S, Zabriskie TM, Proteau PJ, Flatt PM, Santosa DA, Mahmud T. J Nat Prod 2009;72:690–695. [PubMed: 19388705]
9. Yagishita KJ. Antibiot 1960;13:83–96.
10. Osato T, Maeda K, Umezawa H. J Antibiot 1954;7:15–16. [PubMed: 13162942]
11. Laatsch, H. AntiBase, a Natural Products Database for Rapid Structure Determination. Wiley-VCH; Weinheim: 2005.
12. Nakamura S, Maeda K, Umezawa H. J Antibiot 1964;17:33–36. [PubMed: 14109823]
13. Textor A, Papastavrou I, Siewert J, Magull J, Kulik A, Fiedler HP, von Zezschwitz P, Grond S. Chemistry 2007;13:7416–7423. [PubMed: 17583901]
14. Kawahara N, Nakajima S, Kawai K. Phytochemistry 1989;28:1546–1548.

15. Koenuma M, Kinashi H, Otake N. J Antibiot 1974;27:801–804. [PubMed: 4457528]

Figure 1.
Structures of **1a**, **1b**, and **2** and selected HMBC correlations in **2**.

Figure 2.
Structure and selected HMBC correlations in compound **3**.

Figure 3. Structures of pyrones **4a** and **4b** and selected HMBC (single headed arrows) and NOESY (double arrow) correlations in **4b**.

Figure 4.
Hypothetical formation of compounds **2** and **3** from **1b** and **4a**.

Table 1¹H NMR (300 MHz) and ¹³C NMR (75 MHz) Data for Compounds **2** and **3**.^a

2^b			3^c	
position	δ _C , mult.	δ _H (J in Hz)	δ _C , mult.	δ _H (J in Hz)
1	125.5, C	-	116.7/116.6, C	-
2	136.9, CH	8.95, dd (7.2, 1.5)	129.0/128.95, CH	7.75, m
3	130.8, CH	8.04, dd (8.8, 7.2)	118.5/118.3, CH	6.63, m
4	134.9, CH	8.49, dt (8.8, 1.5)	124.9/124.86, CH	7.75, m
4a	142.6, C	-	123.5, C	-
5a	144.2, C	-	123.3/123.2, C	-
6	127.7, ^d C	-	124.4/124.2, C	-
7	133.5, CH	7.72, dd (8.0, 3.5 Hz)	117.4/117.3, CH	6.63, m
8	108.4, CH	7.14, d (8.0)	107.6/107.55, CH	6.63, m
9	153.4, C	-	144.5/144.49, C	-
9a	127.8, ^d C	-	n.d.	-
10a	138.6, C	-	139.2, C	-
1'	34.0/33.6, CH ₂	4.02, m	33.4/33.3, CH ₂	3.22, d (15.4); 2.75, d (15.4)
2'	61.9, C	-	57.7/57.5, C	-
3'	205.0, C	-	205.7/205.6, C	-
4'	57.8/57.7, CH	4.02, m	54.5/54.4, CH	4.24, q (7.0)
5'	207.0, C	-	206.2/206.0, C	-
6'	33.3/32.7, CH ₂	2.58, q (7.2)	33.2, CH ₂	2.27, q (7.2)/2.36, q (7.3)
7'	7.9, CH ₃	1.06, t (7.2)	7.5/7.4, CH ₃	0.77, t (7.2)/0.86, t (7.0)
COOH	166.3, C	-	173.0, C	-
9-OCH ₃	56.6, CH ₃	4.17, s	60.1, CH ₃	3.77, s
CO ₂ CH ₃	173.0, C	-	-	-
CO ₂ CH ₃	52.5/52.7, CH ₃	3.60, s	-	-
2'-CH ₃	19.7/19.1, CH ₃	1.31, s	20.3/20.0, CH ₃	1.33, s/1.35, s
4'-CH ₃	16.5/15.8, CH ₃	1.41, d (7.0)	14.7/14.6, CH ₃	1.09, d (7.0)/1.04, d (7.0)
10-NH	-	-	-	11.39, brs
CON	-	-	168.2/168.1, qC	-

^a Dual entries for some positions indicate doubling of some resonances in the 1D spectra;^b CDCl₃;^c DMSO-*d*₆;^d Assignments may be interchanged; n.d. = not detected